Oral tofacitinib citrate for recalcitrant cutaneous lupus

doi:10.1016/j.jdcr.2021.09.030

Case Reports

. 2021 Oct 2:20:61-64.

doi: 10.1016/j.jdcr.2021.09.030. eCollection 2022 Feb.

Oral tofacitinib citrate for recalcitrant cutaneous lupus

Evelyne Bonnardeaux¹, Jan P Dutz^{1

2}

Affiliations

¹ Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, Canada.
² BC Children's Hospital Research Institute, Vancouver, Canada.

PMID: 35118185
PMCID: PMC8792392
DOI: 10.1016/j.jdcr.2021.09.030

Free PMC article

Case Reports

Oral tofacitinib citrate for recalcitrant cutaneous lupus

Evelyne Bonnardeaux et al. JAAD Case Rep. 2021.

Free PMC article

. 2021 Oct 2:20:61-64.

doi: 10.1016/j.jdcr.2021.09.030. eCollection 2022 Feb.

Authors

Evelyne Bonnardeaux¹, Jan P Dutz^{1

2}

Affiliations

¹ Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, Canada.
² BC Children's Hospital Research Institute, Vancouver, Canada.

PMID: 35118185
PMCID: PMC8792392
DOI: 10.1016/j.jdcr.2021.09.030

No abstract available

Keywords: CLASI, cutaneous lupus erythematosus disease area and severity index; CLE, cutaneous lupus erythematosus; JAK inhibitors; JAK, Janus kinase; Janus kinase; SLE, systemic lupus erythematosus; cutaneous lupus erythematosus; systemic lupus erythematosus; tofacitinib.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

**Fig 1**
Clinical images of patients 1 and 3 before and after tofacitinib treatment for cutaneous lupus erythematosus.

See this image and copyright information in PMC

Cited by

SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.
Pandey R, Bakay M, Hakonarson H. Pandey R, et al. Front Immunol. 2023 Oct 26;14:1271102. doi: 10.3389/fimmu.2023.1271102. eCollection 2023. Front Immunol. 2023. PMID: 38022642 Free PMC article. Review.
Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report.
Hu W, Zhang S, Lian C. Hu W, et al. Clin Cosmet Investig Dermatol. 2023 Oct 9;16:2793-2800. doi: 10.2147/CCID.S419344. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37841060 Free PMC article.
Refractory alopecia in lupus treated with tofacitinib - a case-based review.
Sarkar R, Mv P, Hinduja N, Sethy M, Kar H, Ahmed S. Sarkar R, et al. Clin Rheumatol. 2023 Aug;42(8):2237-2241. doi: 10.1007/s10067-023-06632-6. Epub 2023 May 15. Clin Rheumatol. 2023. PMID: 37188961 Review.
Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
Niebel D, de Vos L, Fetter T, Brägelmann C, Wenzel J. Niebel D, et al. Am J Clin Dermatol. 2023 Jul;24(4):521-540. doi: 10.1007/s40257-023-00774-8. Epub 2023 May 4. Am J Clin Dermatol. 2023. PMID: 37140884 Free PMC article. Review.
Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus.
Huo R, Huang X, Yang Y, Lin J. Huo R, et al. J Inflamm Res. 2023 Apr 6;16:1471-1478. doi: 10.2147/JIR.S397639. eCollection 2023. J Inflamm Res. 2023. PMID: 37051062 Free PMC article. Review.

See all "Cited by" articles

References

1. Kuhn A., Aberer E., Bata-Csörgő Z., et al. S2k guideline for treatment of cutaneous lupus erythematosus–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) J Eur Acad Dermatol Venereol. 2017;31(3):389–404. doi: 10.1111/jdv.14053. - DOI - PubMed
1. Cuadrado M.J., Karim Y., Sanna G., Smith E., Khamashta M.A., Hughes G.R.V. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118(3):246–250. doi: 10.1016/j.amjmed.2004.04.030. - DOI - PubMed
1. Fetter T., Smith P., Guel T., Braegelmann C., Bieber T., Wenzel J. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344. doi: 10.3389/fimmu.2020.00344. - DOI - PMC - PubMed
1. You H., Zhang G., Wang Q., et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi: 10.1136/annrheumdis-2019-215455. - DOI - PubMed
1. Wallace D.J., Furie R.A., Tanaka Y., et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222–231. doi: 10.1016/S0140-6736(18)31363-1. doi: 10.1016/S0140-6736(18)31741-0. Erratum in: Lancet. 2018;392 (10146):476. - DOI - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Kuhn A., Aberer E., Bata-Csörgő Z., et al. S2k guideline for treatment of cutaneous lupus erythematosus–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) J Eur Acad Dermatol Venereol. 2017;31(3):389–404. doi: 10.1111/jdv.14053. - DOI - PubMed

[2] Kuhn A., Aberer E., Bata-Csörgő Z., et al. S2k guideline for treatment of cutaneous lupus erythematosus–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) J Eur Acad Dermatol Venereol. 2017;31(3):389–404. doi: 10.1111/jdv.14053. - DOI - PubMed

[3] Cuadrado M.J., Karim Y., Sanna G., Smith E., Khamashta M.A., Hughes G.R.V. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118(3):246–250. doi: 10.1016/j.amjmed.2004.04.030. - DOI - PubMed

[4] Cuadrado M.J., Karim Y., Sanna G., Smith E., Khamashta M.A., Hughes G.R.V. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118(3):246–250. doi: 10.1016/j.amjmed.2004.04.030. - DOI - PubMed

[5] Fetter T., Smith P., Guel T., Braegelmann C., Bieber T., Wenzel J. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344. doi: 10.3389/fimmu.2020.00344. - DOI - PMC - PubMed

[6] Fetter T., Smith P., Guel T., Braegelmann C., Bieber T., Wenzel J. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344. doi: 10.3389/fimmu.2020.00344. - DOI - PMC - PubMed

[7] You H., Zhang G., Wang Q., et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi: 10.1136/annrheumdis-2019-215455. - DOI - PubMed

[8] You H., Zhang G., Wang Q., et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi: 10.1136/annrheumdis-2019-215455. - DOI - PubMed

[9] Wallace D.J., Furie R.A., Tanaka Y., et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222–231. doi: 10.1016/S0140-6736(18)31363-1. doi: 10.1016/S0140-6736(18)31741-0. Erratum in: Lancet. 2018;392 (10146):476. - DOI - DOI - PubMed

[10] Wallace D.J., Furie R.A., Tanaka Y., et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222–231. doi: 10.1016/S0140-6736(18)31363-1. doi: 10.1016/S0140-6736(18)31741-0. Erratum in: Lancet. 2018;392 (10146):476. - DOI - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Oral tofacitinib citrate for recalcitrant cutaneous lupus

Affiliations

Oral tofacitinib citrate for recalcitrant cutaneous lupus

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources